10-Q: Iris Acquisition Corp Reports Net Loss in Q3 2023 Amidst Business Combination Efforts

Iris Acquisition Corp reported a net loss of $323,891 for the third quarter of 2023, as it continues to pursue a business combination with Liminatus Pharma.

Summary

• Iris Acquisition Corp, a blank check company, reported a net loss of $323,891 for the three months ended September 30, 2023, and a net loss of $739,623 for the nine months ended September 30, 2023.
• The company's operating bank account held $337,721 as of September 30, 2023, with a working capital deficit of $4,191,415.
• The company is pursuing a business combination with Liminatus Pharma, with the deadline extended to March 9, 2024.
• Significant redemptions of public shares occurred, reducing the number of outstanding shares and impacting the cash held in the trust account.
• The company has incurred significant costs related to its formation and the pursuit of a business combination.
• The company's financial statements include a going concern warning due to the working capital deficit and the approaching deadline for completing a business combination.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to the company's net losses, working capital deficit, going concern warning, and the need for multiple extensions to complete the business combination. The high level of redemptions and internal control weaknesses further contribute to the negative sentiment.

Positives

• The company has extended the deadline for completing a business combination to March 9, 2024, providing more time to finalize the deal with Liminatus Pharma.
• The company has secured a promissory note from Liminatus for up to $1,500,000, with $350,000 advanced as of September 30, 2023, providing additional funding.

Negatives

• The company reported a net loss of $323,891 for the three months ended September 30, 2023.
• The company has a significant working capital deficit of $4,191,415 as of September 30, 2023.
• The company's financial statements include a going concern warning, indicating substantial doubt about its ability to continue as a going concern.
• The company has incurred significant costs related to its formation and the pursuit of a business combination.
• The company has experienced significant redemptions of public shares, reducing the cash held in the trust account.
• The company has a promissory note with a related party with an outstanding balance of $1,433,720 as of September 30, 2023.

Risks

• The company's ability to continue as a going concern is in doubt due to its working capital deficit and the approaching deadline for completing a business combination.
• The company may need to obtain additional financing to complete the business combination or to meet its obligations if a significant number of public shares are redeemed.
• If the company is unable to complete the business combination by March 9, 2024, it will be forced to liquidate.
• The company's internal controls over financial reporting were deemed ineffective as of September 30, 2023, due to a material weakness.
• The company is subject to risks related to the ongoing military action in Ukraine and related economic sanctions, which could impact its ability to complete a business combination.
• The application of the 1% excise tax on stock repurchases is unclear and could reduce the value of the company's Class A common stock or cash available for a business combination.

Future Outlook

The company is focused on completing its business combination with Liminatus Pharma by the extended deadline of March 9, 2024, and may need to obtain additional financing to do so. If the business combination is not completed by the deadline, the company will be forced to liquidate.

Management Comments

• Management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company's ability to continue as a going concern.
• Management has determined that if the Company is unable to complete a Business Combination by March 9, 2024, then the Company will cease all operations except for the purpose of liquidating.

Industry Context

The document reflects the challenges faced by many SPACs in finding and completing a business combination within the allotted timeframe, particularly given the recent market volatility and economic uncertainty. The need for extensions and the significant redemptions highlight the pressure on SPACs to deliver value to shareholders.

Comparison to Industry Standards

• The financial performance of Iris Acquisition Corp is below average compared to other SPACs that have successfully completed a business combination.
• The high level of redemptions is a common issue for SPACs, but the magnitude of redemptions for Iris Acquisition Corp is significant and indicates a lack of investor confidence.
• The company's working capital deficit is a concern and is higher than many other SPACs at a similar stage.
• The company's reliance on related party loans is not uncommon for SPACs, but the amount is significant and could pose a risk if the business combination is not completed.
• The company's internal control weaknesses are a concern and are not typical for SPACs that are close to completing a business combination.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a promissory note with a related party with an outstanding balance of $1,433,720 as of September 30, 2023.
• The company has a related party loan agreement where the Sponsor or an affiliate of the Sponsor, or certain of the Company's officers and directors may, but are not obligated to, loan the Company funds as may be required on a non-interest bearing basis.
• The company has an administrative support agreement with an affiliate of the Sponsor, Tribe Capital Markets LLC, for office space, secretarial and administrative services.

Stakeholder Impact

• Shareholders have experienced significant redemptions of their shares, reducing the cash held in the trust account and potentially impacting the value of their investment.
• Employees may be impacted by the uncertainty surrounding the company's future and the potential for liquidation.
• The company's creditors may be at risk if the business combination is not completed and the company is forced to liquidate.
• The company's suppliers and customers may be impacted by the uncertainty surrounding the company's future.

Next Steps

• The company will continue to pursue its business combination with Liminatus Pharma.
• The company may seek additional financing to complete the business combination.
• The company will work to remediate the identified material weakness in its internal controls over financial reporting.

Key Dates

Keywords

business combination, SPAC, Liminatus Pharma, redemption, working capital, going concern, warrants, promissory note, excise tax, financial statements